222 related articles for article (PubMed ID: 302412)
1. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
[TBL] [Abstract][Full Text] [Related]
2. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
3. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study.
Parker LM; Griffiths CT; Yankee RA; Knapp RC; Canellos GP
Cancer Treat Rep; 1979 Feb; 63(2):275-9. PubMed ID: 312692
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue.
Isacoff WH; Morrison PF; Aroesty J; Willis KL; Block JB; Lincoln TL
Cancer Treat Rep; 1977 Dec; 61(9):1665-74. PubMed ID: 304376
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors.
Glode LM; Pitman SW; Ensminger WD; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1979 Sep; 39(9):3707-14. PubMed ID: 383286
[TBL] [Abstract][Full Text] [Related]
7. Thymidine rescue of high-dose methotrexate in humans.
Howell SB; Ensminger WD; Krishan A; Frei E
Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
[TBL] [Abstract][Full Text] [Related]
9. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.
Howell SB; Krishan A; Frei E
Cancer Res; 1979 Apr; 39(4):1315-20. PubMed ID: 311245
[TBL] [Abstract][Full Text] [Related]
10. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.
Pinedo HM; Zaharko DS; Bull J; Chabner BA
Cancer Res; 1977 Feb; 37(2):445-50. PubMed ID: 832268
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
12. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue.
Stoller RG; Kaplan HG; Cummings FJ; Calabresi P
Cancer Res; 1979 Mar; 39(3):908-12. PubMed ID: 311683
[No Abstract] [Full Text] [Related]
13. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.
Evans WE; Crom WR; Abromowitch M; Dodge R; Look AT; Bowman WP; George SL; Pui CH
N Engl J Med; 1986 Feb; 314(8):471-7. PubMed ID: 3456079
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
15. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
16. Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies.
Sasaki K; Tanaka J; Murakami T; Matuoka H; Fujimoto T; Taguchi H
Cancer Drug Deliv; 1985; 2(1):77-86. PubMed ID: 3876873
[TBL] [Abstract][Full Text] [Related]
17. [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].
Janka GE; Wiesner H; Bidlingmaier F; Haas RJ
Klin Wochenschr; 1979 Apr; 57(8):411-6. PubMed ID: 313478
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
[TBL] [Abstract][Full Text] [Related]
19. New approaches to cancer chemotherapy with methotrexate.
Frei E; Jaffe N; Tattersall MH; Pitman S; Parker L
N Engl J Med; 1975 Apr; 292(16):846-51. PubMed ID: 1078714
[No Abstract] [Full Text] [Related]
20. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
